User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Long-term clinical effectiveness of ustekinumab in patients with Crohn's disease who failed biological therapies: a national cohort study.

Primary tabs

download
  • Open access
  • PDF
  • 267.67 K
Liefferinckx, Claire Verstockt, Bram Gils, Ann Noman, Maja Van Kemseke, Catherine Rahier, Jean-François [UCL] Belgian Inflammatory Bowel Disease Research and Development Group (BIRD group)

(eng) BACKGROUND: Ustekinumab [UST] was recently approved in Europe for the treatment of moderate to severe Crohn's disease [CD]. Long-term real-world data are currently scarce for CD patients previously exposed to several biologics. METHODS: This is an observational, national, retrospective multicentre study. Patients received intravenous UST ~6 mg/kg at baseline, with 90 mg subcutaneously thereafter every 8 weeks. Response and remission rates were assessed at Weeks 8, 16, and 52. RESULTS: Data from 152 patients were analysed. All patients were exposed to at least one anti-TNFα agent, with 69.7% were exposed to even two anti-TNFα and vedolizumab. After 1 year, 42.1% and 25.7% of patients had experienced clinical response and clinical remission, respectively, and 38.8% and 24.3% had achieved steroid-free clinical response and remission, respectively; 38.8% of patients discontinued therapy during the 12 months of follow-up. Colonic location was predictive of clinical response at 1 year, and low body mass index [BMI] at baseline was a negative predictor of clinical remission. Resolution of arthralgia was associated with clinical response over time. De novo arthralgia was reported by 17.9% of patients at Week 8 and 13.5% of patients at Week 52. No impact of UST on arthralgia was observed in patients with concomitant ankylosing spondylitis [n = 17]. Others adverse events were reported in 7.2% of patients. CONCLUSIONS: This real-world cohort study confirms the effectiveness of UST in CD patients previously exposed to several biologics. Ustekinumab was well tolerated with respect to adverse events. PODCAST: This article has an associated podcast which can be accessed at https://academic.oup.com/ecco-jcc/pages/podcast.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2019
Language Anglais
Journal information "Journal of Crohn's & colitis" - Vol. 13, no. 11, p. 1401-1409 (2019)
Peer reviewed yes
Publisher Oxford University Press ((United Kingdom) Oxford)
issn 1873-9946
e-issn 1876-4479
Publication status Publié
Affiliations UCL - (MGD) Service de gastro-entérologie
UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie
Keywords Clinical ; Crohn’s disease ; effectiveness ; real-life cohort ; ustekinumab
Links
  1. Hanauer Stephen B, Feagan Brian G, Lichtenstein Gary R, Mayer Lloyd F, Schreiber S, Colombel Jean Frederic, Rachmilewitz Daniel, Wolf Douglas C, Olson Allan, Bao Weihang, Rutgeerts Paul, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, 10.1016/s0140-6736(02)08512-4
  2. Sandborn William J., Feagan Brian G., Rutgeerts Paul, Hanauer Stephen, Colombel Jean-Frédéric, Sands Bruce E., Lukas Milan, Fedorak Richard N., Lee Scott, Bressler Brian, Fox Irving, Rosario Maria, Sankoh Serap, Xu Jing, Stephens Kristin, Milch Catherine, Parikh Asit, Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease, 10.1056/nejmoa1215739
  3. Colombel Jean–Frédéric, Sandborn William J., Rutgeerts Paul, Enns Robert, Hanauer Stephen B., Panaccione Remo, Schreiber Stefan, Byczkowski Dan, Li Ju, Kent Jeffrey D., Pollack Paul F., Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial, 10.1053/j.gastro.2006.11.041
  4. Teng Michele W L, Bowman Edward P, McElwee Joshua J, Smyth Mark J, Casanova Jean-Laurent, Cooper Andrea M, Cua Daniel J, IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases, 10.1038/nm.3895
  5. Benson Jacqueline M, Sachs Clifford W, Treacy George, Zhou Honghui, Pendley Charles E, Brodmerkel Carrie M, Shankar Gopi, Mascelli Mary A, Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab, 10.1038/nbt.1903
  6. Engel Tal, Kopylov Uri, Ustekinumab in Crohn’s disease: evidence to date and place in therapy, 10.1177/2040622316653306
  7. Sandborn William J., Gasink Christopher, Gao Long-Long, Blank Marion A., Johanns Jewel, Guzzo Cynthia, Sands Bruce E., Hanauer Stephen B., Targan Stephan, Rutgeerts Paul, Ghosh Subrata, de Villiers Willem J.S., Panaccione Remo, Greenberg Gordon, Schreiber Stefan, Lichtiger Simon, Feagan Brian G., Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease, 10.1056/nejmoa1203572
  8. Sandborn William J., Feagan Brian G., Fedorak Richard N., Scherl Ellen, Fleisher Mark R., Katz Seymour, Johanns Jewel, Blank Marion, Rutgeerts Paul, A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease, 10.1053/j.gastro.2008.07.014
  9. Simon Ebby G., Ghosh Subrata, Iacucci Marietta, Moran Gordon W., Ustekinumab for the treatment of Crohn’s disease: can it find its niche?, 10.1177/1756283x15618130
  10. Feagan Brian G., Sandborn William J., Gasink Christopher, Jacobstein Douglas, Lang Yinghua, Friedman Joshua R., Blank Marion A., Johanns Jewel, Gao Long-Long, Miao Ye, Adedokun Omoniyi J., Sands Bruce E., Hanauer Stephen B., Vermeire Severine, Targan Stephan, Ghosh Subrata, de Villiers Willem J., Colombel Jean-Frédéric, Tulassay Zsolt, Seidler Ursula, Salzberg Bruce A., Desreumaux Pierre, Lee Scott D., Loftus Edward V., Dieleman Levinus A., Katz Seymour, Rutgeerts Paul, Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease, 10.1056/nejmoa1602773
  11. Kopylov U., Afif W., Cohen A., Bitton A., Wild G., Bessissow T., Wyse J., Al-Taweel T., Szilagyi A., Seidman E., Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience, 10.1016/j.crohns.2014.06.005
  12. Khorrami Sam, Ginard Daniel, Marín-Jiménez Ignacio, Chaparro María, Sierra Mónica, Aguas Mariam, Sicilia Beatriz, García-Sánchez Valle, Suarez Cristina, Villoria Albert, Taxonera Carlos, Velasco-Guardado Antonio, Martínez-González Javier, Gisbert Javier P., Ustekinumab for the Treatment of Refractory Crohnʼs Disease : The Spanish Experience in a Large Multicentre Open-label Cohort, 10.1097/mib.0000000000000842
  13. Harris Kimberly A., Horst Sara, Gadani Akash, Nohl Anne, Annis Kim, Duley Caroline, Beaulieu Dawn, Ghazi Leyla, Schwartz David A., Patients with Refractory Crohnʼs Disease Successfully Treated with Ustekinumab : , 10.1097/mib.0000000000000624
  14. Marini J C, Gils A, Shankar G, Peeters M, Brouwers E, van Iperen P, Le Bars M, Bevalander G S, Sattin B, Sloan S, P649 Comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R&D and used in clinical studies of IBD patients, 10.1093/ecco-jcc/jjx180.776
  15. Wils P., Bouhnik Y., Michetti P., Flourie B., Brixi H., Bourrier A., Allez M., Duclos B., Serrero M., Buisson A., Amiot A., Fumery M., Roblin X., Peyrin-Biroulet L., Filippi J., Bouguen G., Abitbol V., Coffin B., Simon M., Laharie D., Pariente B., , Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience, 10.1111/apt.14487
  16. Ma C., Fedorak R. N., Kaplan G. G., Dieleman L. A., Devlin S. M., Stern N., Kroeker K. I., Seow C. H., Leung Y., Novak K. L., Halloran B. P., Huang V. W., Wong K., Blustein P. K., Ghosh S., Panaccione R., Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort, 10.1111/apt.14016
  17. Arnott I. D. R., McNeill G., Satsangi J., An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease, 10.1046/j.1365-2036.2003.01574.x
  18. Cleynen Isabelle, Boucher Gabrielle, Jostins Luke, Schumm L Philip, Zeissig Sebastian, Ahmad Tariq, Andersen Vibeke, Andrews Jane M, Annese Vito, Brand Stephan, Brant Steven R, Cho Judy H, Daly Mark J, Dubinsky Marla, Duerr Richard H, Ferguson Lynnette R, Franke Andre, Gearry Richard B, Goyette Philippe, Hakonarson Hakon, Halfvarson Jonas, Hov Johannes R, Huang Hailang, Kennedy Nicholas A, Kupcinskas Limas, Lawrance Ian C, Lee James C, Satsangi Jack, Schreiber Stephan, Théâtre Emilie, van der Meulen-de Jong Andrea E, Weersma Rinse K, Wilson David C, Parkes Miles, Vermeire Severine, Rioux John D, Mansfield John, Silverberg Mark S, Radford-Smith Graham, McGovern Dermot P B, Barrett Jeffrey C, Lees Charlie W, Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study, 10.1016/s0140-6736(15)00465-1
  19. Papp, J Drugs Dermatol, 14, 706 (2015)
  20. Wils, J Crohns Colitis, 9 Suppl 1, S37 (2015)
  21. McInnes Iain B, Kavanaugh Arthur, Gottlieb Alice B, Puig Lluís, Rahman Proton, Ritchlin Christopher, Brodmerkel Carrie, Li Shu, Wang Yuhua, Mendelsohn Alan M, Doyle Mittie K, Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial, 10.1016/s0140-6736(13)60594-2
  22. Ritchlin Christopher, Rahman Proton, Kavanaugh Arthur, McInnes Iain B, Puig Lluis, Li Shu, Wang Yuhua, Shen Yaung-Kaung, Doyle Mittie K, Mendelsohn Alan M, Gottlieb Alice B, , Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial, 10.1136/annrheumdis-2013-204655
  23. Deodhar Atul, Gensler Lianne S., Sieper Joachim, Clark Michael, Calderon Cesar, Wang Yuhua, Zhou Yiying, Leu Jocelyn H., Campbell Kim, Sweet Kristen, Harrison Diane D., Hsia Elizabeth C., Heijde Désirée, Ariel Frederico, Asnal Cecilia Adma, Berman Alberto, Citera Gustavo, Rodriguez Graciela, Savio Veronica Gabriela, Bird Paul, Griffiths Hedley, Nicholls David, Rischmueller Maureen, Zochling Jane, De Vlam Kurt, Malaise Michel, Toukap Adrien Nzeusseu, Van den Bosch Filip, Vanhoof Johan, Bonfiglioli Rubens, Keiserman Mauro, Scotton Antonio Scafuto, Xavier Ricardo, Ximenes Antonio Carlos, Atanasov Assen, Goranov Ivan, Kazmin Ivan, Licheva Rodina Nestorova, Nikolov Nikolay, Oparanov Boycho, Stoilov Rumen, Bessette Louis, Rodrigues Jude, Bortilik Ladislav, Dokoupilova Eva, Dvoarak Zdenek, Galatikova Dagmar, Nemec Petr, Podrazilova Lucie, Simkova Gabriela, Stejfova Zuzana, Moravcova Radka, Vitek Petr, Cantagrel Alain, Baillet Athan, Banneville Beatrice, Combe Bernard, Breban Maxime, Nguyen Minh, Goupille Philippe, Braun Juergen, Everding Andrea, Kekow Joern, Koenig Ramona, Rubbert‐Roth Andrea, Witte Torsten, Bartha Attila, Drescher Edit, Kerekes Kata, Kovacs Attila, Pulai Judit, Rojkovich Bernadette, Szanto Sandor, Toth Edit, Avila Hilario, Torre Igancio Garcia, Irazoque Fedra, Maradiaga Marco, Pacheco Cesar, Brzosko Marek, Dudek Anna, Jeka Slawomir, Krogulec Marek, Kwiatkowska Brygida, Wiland Piotr, Wojciechowski Rafal, Zielinska Agnieszka, Santos Helena, Bugrova Olga, Christyakov Valery, Gorbunov Vladimir, Ilivanova Elena, Zemerova Elena, Kamalova Rima, Kameneva Tatyana, Macievskaya Galina, Marusenko Irina, Maslyansky Alexey, Myasoedova Svetlana, Myasoutova Leisan, Nemtsov Boris, Nesmeyanova Olga, Plaksina Tatyana, Pokrovskaya Tatyana, Polyakova Svetlana, Rebrov Andrey, Savina Liudmila, Smakotina Svetlana, Stanislav Marina, Ukhanova Olga, Vinogradova Irina, Zonova Elena, Baek Han Joo, Kim Tae‐Hwan, Lee ChangKeun, Lee SangHeon, Lee Sang‐Hoon, Lee Shin‐Seok, Park Sung‐Hwan, Song YeongWook, Suh Chang‐Hee, Ramos Juan Amarelo, Blanco Franciso Javier, Collantes Eduardo, Diaz Miguel Consuelo, Vivar Maria Luz Garcia, Gratacos Jordi, Juanola Xavier, Chen Der‐Yuan, Chen Hsiang‐Cheng, Chen Kun‐Hung, Chen Ying‐Chou, Chiu Ying‐Ming, Luo Shue‐Fen, Tsai Shih‐Tzu, Tseng Jui‐Cheng, Wei Cheng‐Chung, Weng Meng‐Yu, Abrahamovych Orest, Reshotko Dmytro, Golovchenko Oleksandr, Hospodarsky Ihor, Iaremenko Oleg, Levchenko Olena, Dudnyk Oleksandr, Garmish Olena, Grishyna Olena, Protsenko Galyna, Rekalov Dmytro, Smiyan Svitlana, Stanislavchuk Mykola, Trypilka Svitlana, Tseluyko Vira, Turianytsia Samvel, Vasylets Viktoriya, Virstyuk Nataliya, Kleban Yaroslav, Ciurtin Coziana, Gaffney Karl, Gunasekera Wiranthi, Mackay Kirsten, Packham Jon, Sengupta Raj, Tahir Hasan, Aelion Jacob, Bennett Ralph, Deodhar Atul, Gonzalez‐Paoli Julio, Griffin Robert M., Grisanti Michael, Mallepalli Jyothi, Peters Eric, Schechtman Joy, Singhal Atul, Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis, 10.1002/art.40728
  24. Tadbiri S., Peyrin-Biroulet L., Serrero M., Filippi J., Pariente B., Roblin X., Buisson A., Stefanescu C., Trang-Poisson C., Altwegg R., Marteau P., Vaysse T., Bourrier A., Nancey S., Laharie D., Allez M., Savoye G., Gilletta C., Gagniere C., Vuitton L., Viennot S., Aubourg A., Pelletier A.-L., Bouguen G., Abitbol V., Fumery M., Claudepierre P., Bouhnik Y., Amiot A., , Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort, 10.1111/apt.14419
  25. Battat Robert, Kopylov Uri, Bessissow Talat, Bitton Alain, Cohen Albert, Jain Anjali, Martel Myriam, Seidman Ernest, Afif Waqqas, Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn’s Disease, 10.1016/j.cgh.2017.03.032
  26. Rowan C. R., Keegan D., Byrne K., Cullen G., Mulcahy H. E., Sheridan J., Ryan E. J., de Vries A., D'Haens G., Doherty G. A., Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study, 10.1111/apt.14834
  27. Adedokun Omoniyi J., Xu Zhenhua, Gasink Christopher, Jacobstein Douglas, Szapary Philippe, Johanns Jewel, Gao Long-Long, Davis Hugh M., Hanauer Stephen B., Feagan Brian G., Ghosh Subrata, Sandborn William J., Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease, 10.1053/j.gastro.2018.01.043
Bibliographic reference Liefferinckx, Claire ; Verstockt, Bram ; Gils, Ann ; Noman, Maja ; Van Kemseke, Catherine ; et. al. Long-term clinical effectiveness of ustekinumab in patients with Crohn's disease who failed biological therapies: a national cohort study.. In: Journal of Crohn's & colitis, Vol. 13, no. 11, p. 1401-1409 (2019)
Permanent URL http://hdl.handle.net/2078.1/217907